Addex Therapeutics appoints Jean-Philippe Rocher head of pharmaceutical development
ADXN•Addex Therapeutics named Jean-Philippe Rocher head of pharmaceutical development and added him to executive management. Mikhail Kalinichev stepped down as head of translational science to take a similar role at Neurosterix.
1. Leadership changes
Rocher previously led pharmaceutical development at Neurosterix, joined Addex at its inception in 2002, and later served as CNS program director at Pierre Fabre. Kalinichev stepped down as head of translational science to focus on a similar role at Neurosterix.
